George Washington University School of Medicine and Health Sciences, Washington, DC, and Brigham and Women's Hospital, Boston, Massachusetts.
Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Arthritis Care Res (Hoboken). 2019 Dec;71(12):1621-1629. doi: 10.1002/acr.23803. Epub 2019 Nov 5.
To evaluate the cost-effectiveness of prolonged (35-day) and standard-duration (14-day) anticoagulation therapy following total knee arthroplasty (TKA).
Using Markov modeling, we assessed clinical and economic outcomes of 14-day and 35-day anticoagulation therapy following TKA with rivaroxaban, low molecular weight heparin (LMWH), fondaparinux, warfarin, and aspirin. Incidence of complications of TKA and anticoagulation therapy (deep vein thrombosis [DVT], pulmonary embolism [PE], prosthetic joint infection [PJI], and bleeding) were derived from published literature. Daily costs ranged from $1 (aspirin) to $43 (fondaparinux). Primary outcomes included quality-adjusted life years (QALYs), direct medical costs, and incremental cost-effectiveness ratios (ICERs) at 1 year post-TKA. The preferred regimen was the regimen with highest QALYs maintaining an ICER below the willingness-to-pay threshold ($100,000/QALY). We conducted probabilistic sensitivity analyses, varying complication incidence and anticoagulation efficacy, to evaluate the impact of parameter uncertainty on model results.
Aspirin resulted in the highest cumulative incidence of DVT and PE, while prolonged fondaparinux led to the largest reduction in DVT incidence (15% reduction compared to no prophylaxis). Despite differential bleeding rates (ranging from 3% to 6%), all strategies had similar incidence of PJI (1% to 2%). Prolonged rivaroxaban was the least costly strategy ($3,300 at 1 year post-TKA) and the preferred regimen in the base case. In sensitivity analyses, prolonged rivaroxaban and warfarin had similar likelihoods of being cost-effective.
Extending postoperative anticoagulation therapy to 35 days increases QALYs compared to standard 14-day prophylaxis. Prolonged rivaroxaban and prolonged warfarin are most likely to be cost-effective post-TKA; the costs of fondaparinux and LMWH precluded their being preferred strategies.
评估全膝关节置换术后(TKA)延长(35 天)和标准疗程(14 天)抗凝治疗的成本效益。
我们使用马尔可夫模型,评估了利伐沙班、低分子肝素(LMWH)、磺达肝癸钠、华法林和阿司匹林治疗 TKA 后 14 天和 35 天抗凝治疗的临床和经济结局。TKA 和抗凝治疗(深静脉血栓形成 [DVT]、肺栓塞 [PE]、人工关节感染 [PJI] 和出血)并发症的发生率来自已发表的文献。每日费用从 1 美元(阿司匹林)到 43 美元(磺达肝癸钠)不等。主要结局包括 TKA 后 1 年的质量调整生命年(QALY)、直接医疗成本和增量成本效益比(ICER)。首选方案是 QALY 最高且 ICER 低于支付意愿阈值(100,000 美元/QALY)的方案。我们进行了概率敏感性分析,改变了并发症发生率和抗凝疗效,以评估参数不确定性对模型结果的影响。
阿司匹林导致 DVT 和 PE 的累积发生率最高,而延长磺达肝癸钠导致 DVT 发生率最大降低(与无预防措施相比降低 15%)。尽管出血率存在差异(3%至 6%),但所有策略的 PJI 发生率相似(1%至 2%)。延长利伐沙班是最具成本效益的策略(TKA 后 1 年的 3300 美元),也是基础病例中的首选方案。在敏感性分析中,延长利伐沙班和华法林具有相似的成本效益可能性。
与标准的 14 天预防治疗相比,延长术后抗凝治疗至 35 天可增加 QALY。延长利伐沙班和延长华法林治疗 TKA 后最有可能具有成本效益;磺达肝癸钠和 LMWH 的成本排除了它们成为首选策略的可能性。